Evidence map›Paper›PMID 40654760›Full record

ArticlebioRxiv : the preprint server for biology2025

13C tracing in synaptosomes reveals that SGLT2 inhibition with dapagliflozin prevents metabolic deficits in the 5X-FAD model of Alzheimer's Disease.

Marisa Mekkittikul, Cansheng Zhu, Bezawit T Danna, Xiaohong Zuo, Amy Rios, Krista Yang, Miranda Villanueva, Devanshi Agarwal, Daniel Castro, Xuelin Gu and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marisa MekkittikulDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Cansheng ZhuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Bezawit T DannaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Xiaohong ZuoDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Amy RiosDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Krista YangDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Miranda VillanuevaDepartment of Biological Chemistry, University of California, Los Angeles, Los Angeles, CA, USA.
Devanshi AgarwalDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Daniel CastroDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Xuelin GuDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Alexander R StrofsDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Orian S ShirihaiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Linsey StilesDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Sally A FrautschyDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Jan OscarssonLate-Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Russell L EsterlineLate-Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, United States.
Gregory M ColeDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Ajit S DivakaruniDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-2528-9651

Funding

Metabolic and Vascular Factors in tau pathogenesisR01AG066212 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FRAUTSCHY, SALLY ANN · 2020 to 2024
$3.4M
Understanding How Metabolic Cofactors Control Cell Function and FateR35GM138003 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Ajit Divakaruni · 2020 to 2026
$2.8M
Chemistry Biology Interface Training ProgramT32GM136614 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Patrick G. Harran · 2020 to 2026
$2.8M
BLRD VA I01 BX003485BLRD VA I01 BX005919NIA NIH HHS R01 AG066212NIGMS NIH HHS R35 GM138003NIGMS NIH HHS T32 GM136614
6 · The paper itself

Abstract

Metabolic dysfunction is linked to several forms of age-related neurodegeneration including Alzheimer's Disease (AD), and targeting brain energy metabolism is an increasingly attractive mode of therapeutic intervention. However, commonly used

Identifiers

PMID40654760
PMCPMC12247946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.